US Edition
Trinity Biotech reports positive outcomes with next-gen CGM
Summary by Drug Delivery Business
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Trinity Biotech reports positive outcomes with next-gen CGM
The slim profile of the CGM+ sensor. [Image courtesy of Trinity Biotech]Trinity Biotech (Nasdaq:TRIB) today announced positive clinical trial results for its next-generation continuous glucose monitor (CGM). Dublin, Ireland-based Trinity Biotech unveiled its CGM+ next-gen wearable biosensor last month. With CGM+, the company aims to take on the growing AI wearables market. The company said it has the system in the later stages of device developm…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
